SERD and CDK4/6 Inhibitor Combination Therapy for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for estrogen receptor-positive breast cancers, such as tamoxifen and aromatase inhibitors, often fail to respond or develop resistance within five years, making it challenging to effectively treat hormone-sensitive and resistant tumors.
Innovation Solution
A combination therapy using a selective estrogen receptor downregulator (SERD) compound, such as Compound 20, in conjunction with a CDK 4/6 inhibitor, like Compound 23, administered in a pharmaceutical composition to target and inhibit estrogen receptor-positive cell proliferation and resistance mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tamoxifen or aromatase inhibitors are used as first-line treatment for ER+ breast cancer, then initial treatment response is achieved, but resistance develops within five years in almost 50% of patients
Solution Approach 1:
The patent combines a SERD compound (Formula A, B, or C) with a CDK 4/6 inhibitor (Formula D) into a single pharmaceutical composition or combination therapy. This merging of two different mechanisms of action (estrogen receptor downregulation and cell cycle inhibition) aims to overcome resistance that develops with single-agent therapy, thereby extending the duration of treatment effectiveness and improving reliability of long-term response.
Solution Approach 2:
The invention creates a composite therapeutic approach by formulating a pharmaceutical composition containing both the SERD compound and CDK 4/6 inhibitor. This composite therapy targets multiple pathways simultaneously (estrogen signaling and cell cycle progression), preventing the development of resistance that occurs with monotherapy and extending effective treatment duration beyond what either agent achieves alone.
2Reliability
If SERD compounds are used to downregulate estrogen receptors, then hormone-sensitive tumor growth is inhibited, but resistance mechanisms can still develop
Solution Approach 1:
By combining the SERD compound (which downregulates estrogen receptors and inhibits hormone-sensitive growth) with the CDK 4/6 inhibitor (which blocks cell cycle progression at the G1/S transition), the therapy targets two critical pathways simultaneously. This dual targeting prevents cancer cells from adapting and developing resistance through alternative pathways, thereby maintaining reliable tumor growth inhibition over time.
Solution Approach 2:
The CDK 4/6 inhibitor acts as an intermediary mechanism that blocks cell cycle progression independently of estrogen receptor status. Even when cancer cells develop adaptations to SERD therapy, the CDK 4/6 inhibitor provides an additional layer of control over cell division, preventing resistance-mediated tumor progression.
3Reliability
If combination therapy with SERD and CDK 4/6 inhibitor is administered, then potency in inhibiting cell proliferation is improved, but treatment complexity increases
Solution Approach 1:
The patent merges the SERD compound and CDK 4/6 inhibitor into a single pharmaceutical composition or coordinated administration regimen. This integration simplifies the therapeutic complexity by providing a unified treatment protocol rather than requiring separate, uncoordinated therapies, while maintaining the enhanced potency of dual mechanism action.
Data Source
AI summary
Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.